

Adrian G Sacher

List of Publications by Citations

Source: <https://exaly.com/author-pdf/1372495/adrian-g-sacher-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

62

papers

2,651

citations

21

h-index

51

g-index

67

ext. papers

3,769

ext. citations

7

avg, IF

5.15

L-index

#	Paper	IF	Citations
62	KRAS Inhibition with Sotorasib in Advanced Solid Tumors. <i>New England Journal of Medicine</i> , 2020 , 383, 1207-1217	59.2	469
61	Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer. <i>JAMA Oncology</i> , 2016 , 2, 1014-22	13.4	412
60	Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients. <i>Clinical Cancer Research</i> , 2016 , 22, 915-22	12.9	177
59	Sotorasib for Lung Cancers with p.G12C Mutation. <i>New England Journal of Medicine</i> , 2021 , 384, 2371-2381	59.2	168
58	Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non-Small-Cell Lung Cancer: A Review. <i>JAMA Oncology</i> , 2016 , 2, 1217-22	13.4	165
57	Chemical genetics reveals a complex functional ground state of neural stem cells. <i>Nature Chemical Biology</i> , 2007 , 3, 268-73	11.7	135
56	PD-L1 expression in non-small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens. <i>Cancer Cytopathology</i> , 2017 , 125, 896-907	3.9	119
55	Association Between Younger Age and Targetable Genomic Alterations and Prognosis in Non-Small-Cell Lung Cancer. <i>JAMA Oncology</i> , 2016 , 2, 313-20	13.4	106
54	Identification of a bone marrow-derived epithelial-like population capable of repopulating injured mouse airway epithelium. <i>Journal of Clinical Investigation</i> , 2009 , 119, 336-48	15.9	106
53	Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer. <i>Cancer Discovery</i> , 2016 , 6, 1334-1341	24.4	94
52	Targeted cell replacement with bone marrow cells for airway epithelial regeneration. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2007 , 293, L740-52	5.8	81
51	Elderly patients with advanced NSCLC in phase III clinical trials: are the elderly excluded from practice-changing trials in advanced NSCLC?. <i>Journal of Thoracic Oncology</i> , 2013 , 8, 366-8	8.9	72
50	Application of Plasma Genotyping Technologies in Non-Small Cell Lung Cancer: A Practical Review. <i>Journal of Thoracic Oncology</i> , 2017 , 12, 1344-1356	8.9	67
49	Real-world chemotherapy treatment patterns in metastatic non-small cell lung cancer: Are patients undertreated?. <i>Cancer</i> , 2015 , 121, 2562-9	6.4	56
48	Treatment of the elderly when cure is the goal: the influence of age on treatment selection and efficacy for stage III non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2011 , 6, 537-44	8.9	44
47	Talimogene laherparepvec (T-Vec) for the treatment of melanoma and other cancers. <i>Seminars in Oncology</i> , 2016 , 43, 638-646	5.5	38
46	Shifting patterns in the interpretation of phase III clinical trial outcomes in advanced non-small-cell lung cancer: the bar is dropping. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1407-11	2.2	36

45	Fulvestrant for advanced breast cancer: a meta-analysis. <i>Cancer Treatment Reviews</i> , 2013 , 39, 753-8	14.4	26
44	Management of acquired resistance to epidermal growth factor receptor kinase inhibitors in patients with advanced non-small cell lung cancer. <i>Cancer</i> , 2014 , 120, 2289-98	6.4	25
43	New drugs for brain tumors? Insights from chemical probing of neural stem cells. <i>Medical Hypotheses</i> , 2009 , 72, 683-7	3.8	24
42	Financial Burden Among Patients With Lung Cancer in a Publically Funded Health Care System. <i>Clinical Lung Cancer</i> , 2019 , 20, 231-236	4.9	21
41	Phase I study of local radiation and tremelimumab in patients with inoperable locally recurrent or metastatic breast cancer. <i>Oncotarget</i> , 2019 , 10, 2947-2958	3.3	17
40	Subtypes of EGFR- and HER2-Mutant Metastatic NSCLC Influence Response to Immune Checkpoint Inhibitors. <i>Clinical Lung Cancer</i> , 2021 , 22, 253-259	4.9	17
39	A drug discovery platform to identify compounds that inhibit EGFR triple mutants. <i>Nature Chemical Biology</i> , 2020 , 16, 577-586	11.7	15
38	Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non-small cell lung cancer: A real-world multicentre study. <i>European Journal of Cancer</i> , 2021 , 142, 83-91	7.5	15
37	Next-generation sequencing informs diagnosis and identifies unexpected therapeutic targets in lung squamous cell carcinomas. <i>Lung Cancer</i> , 2020 , 140, 35-41	5.9	12
36	Co-clinical quantitative tumor volume imaging in ALK-rearranged NSCLC treated with crizotinib. <i>European Journal of Radiology</i> , 2017 , 88, 15-20	4.7	10
35	Tobacco exposure and immunotherapy response in PD-L1 positive lung cancer patients. <i>Lung Cancer</i> , 2020 , 150, 159-163	5.9	10
34	Taking the stress out of morning report: an analytic approach to the differential diagnosis. <i>Journal of General Internal Medicine</i> , 2009 , 24, 747-51	4	10
33	Early Intervention in Lung Cancers With Rapid Plasma Genotyping for EGFR and KRAS Mutations-Reply. <i>JAMA Oncology</i> , 2016 , 2, 1096-7	13.4	10
32	The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2021 , 160, 136-151	5.9	10
31	The presence and variant allele fraction of EGFR mutations in ctDNA and development of resistance. <i>Lung Cancer</i> , 2019 , 131, 86-89	5.9	9
30	Development of the Functional Assessment of Cancer Therapy-Immune Checkpoint Modulator (FACT-ICM): A toxicity subscale to measure quality of life in patients with cancer who are treated with ICMs. <i>Cancer</i> , 2020 , 126, 1550-1558	6.4	9
29	Cytotoxic CD4 T Cells in Bladder Cancer-A New License to Kill. <i>Cancer Cell</i> , 2020 , 38, 28-30	24.3	7
28	Real-world health utility scores and toxicities to tyrosine kinase inhibitors in epidermal growth factor receptor mutated advanced non-small cell lung cancer. <i>Cancer Medicine</i> , 2019 , 8, 7542-7555	4.8	6

27	BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancer. <i>Lung Cancer</i> , 2020 , 146, 78-85	5.9	6
26	A window of opportunity study of potential tumor and soluble biomarkers of response to preoperative erlotinib in early stage non-small cell lung cancer. <i>Oncotarget</i> , 2016 , 7, 25632-9	3.3	6
25	ALK-rearranged lung adenocarcinoma transformation into high-grade large cell neuroendocrine carcinoma: Clinical and molecular description of two cases. <i>Lung Cancer</i> , 2020 , 146, 350-354	5.9	5
24	Non-small cell lung cancer (NSCLC) next generation sequencing (NGS) using the OncoPrint Comprehensive Assay (OCA) v3: Integrating expanded genomic sequencing into the Canadian publicly funded health care model.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2620-2620	2.2	5
23	Monitoring of Response and Resistance in Plasma of EGFR-Mutant Lung Cancer Using Droplet Digital PCR. <i>Methods in Molecular Biology</i> , 2018 , 1768, 193-207	1.4	4
22	In Faint Praise of the World Bank's Gender Development Policy. <i>Canadian Journal of Sociology</i> , 2005 , 30, 95-111	0.9	3
21	Natural Killer Cells and Type 1 Innate Lymphoid Cells in Hepatocellular Carcinoma: Current Knowledge and Future Perspectives. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	3
20	Prevalence and Heterogeneity of PD-L1 Expression by 22C3 Assay in Routine Population-Based and Reflexive Clinical Testing in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 1490-1500	8.9	3
19	Early Detection of Multiple Resistance Mechanisms by ctDNA Profiling in a Patient With EGFR-mutant Lung Adenocarcinoma Treated With Osimertinib. <i>Clinical Lung Cancer</i> , 2020 , 21, e488-e492	4.9	2
18	Long-term survival of a patient with glioblastoma. <i>Canadian Journal of Neurological Sciences</i> , 2010 , 37, 289-92	1	2
17	Chemical Genetics Screen Identifies COPB2 Tool Compounds That Alters ER Stress Response and Induces RTK Dysregulation in Lung Cancer Cells. <i>Journal of Molecular Biology</i> , 2021 , 433, 167294	6.5	2
16	EGFR-mutated lung adenocarcinomas from patients who progressed on EGFR-inhibitors show high engraftment rates in xenograft models. <i>Lung Cancer</i> , 2020 , 145, 144-151	5.9	2
15	Durability of CNS disease control in NSCLC patients with brain metastases treated with immune checkpoint inhibitors plus cranial radiotherapy. <i>Lung Cancer</i> , 2021 , 156, 76-81	5.9	2
14	Clinicopathologic factors that influence prognosis and survival outcomes in men with metastatic castration-resistant prostate cancer treated with Radium-223. <i>Cancer Medicine</i> , 2021 , 10, 5775-5782	4.8	2
13	The promise and pitfalls of the many methods of plasma genotyping. <i>Expert Opinion on Biological Therapy</i> , 2016 , 16, 1313-1316	5.4	1
12	Concurrent Chemoradiation With or Without Durvalumab in Elderly Patients With Unresectable Stage III NSCLC: Safety and Efficacy.. <i>JTO Clinical and Research Reports</i> , 2021 , 2, 100251	1.4	1
11	Prediction of lung cancer genotype noninvasively using droplet digital PCR (ddPCR) analysis of cell-free plasma DNA (cfDNA).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 8059-8059	2.2	1
10	The impact of symptoms and comorbidity on health utility scores and health-related quality of life in small cell lung cancer using real world data. <i>Quality of Life Research</i> , 2021 , 30, 445-454	3.7	1

9	Systemic Inflammatory Markers of Survival in Epidermal Growth Factor-Mutated Non-Small-Cell Lung Cancer: Single-Institution Analysis, Systematic Review, and Meta-analysis. <i>Clinical Lung Cancer</i> , 2021 , 22, 390-407	4.9	1
8	Integrating comprehensive genomic sequencing of non-small cell lung cancer into a public healthcare system.. <i>Cancer Treatment and Research Communications</i> , 2022 , 31, 100534	2	1
7	New Strategies and Combinations to Improve Outcomes in Immunotherapy in Metastatic Non-Small-Cell Lung Cancer.. <i>Current Oncology</i> , 2021 , 29, 38-55	2.8	0
6	Genomic characterization of non-schistosomiasis-related squamous cell carcinoma of the urinary bladder: A retrospective exploratory study. <i>PLoS ONE</i> , 2021 , 16, e0259272	3.7	0
5	Feasibility study of microbial ecosystem therapeutics (MET-4) to evaluate effects of fecal microbiome in patients on immunotherapy (MET4-IO).. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS2664-TPS2664	2.2	0
4	Myeloid immunosuppressive state as a predictor of rapidly progressive phenotype and poor survival in advanced non-small cell lung cancer (NSCLC) patients treated with PD-1/PD-L1 inhibitors.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e20594-e20594	2.2	0
3	Comparing health utility scores, treatments, and outcomes in lung cancer patients with rare EGFR mutations with those with exon 19 deletion (del) and L858R mutations.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 102-102	2.2	0
2	Fundamental Concepts in the Application of Plasma Genotyping (Liquid Biopsy) to Mutation Detection in Non-Small-Cell Lung Cancer.. <i>JCO Precision Oncology</i> , 2018 , 2, 1-12	3.6	0
1	Survival outcomes of metastatic renal cell carcinoma (mRCC) with sarcomatoid differentiation (SD): A single-institutional experience and literature meta-analysis.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 332-332	2.2	0